Sienna Biopharmaceuticals (SNNAQ)
OTHER OTC:SNNAQ
US Market
Holding SNNAQ?
Track your performance easily

Sienna Biopharmaceuticals (SNNAQ) Income Statement

70 Followers

Sienna Biopharmaceuticals Income Statement

Last quarter (Q ), Sienna Biopharmaceuticals's total revenue was $27.00K, an increase of Infinity% from the same quarter last year. In Q, Sienna Biopharmaceuticals's net income was $-3.97M. See Sienna Biopharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 18Dec 17Dec 16Dec 15
Total Revenue
$ 54.00K--$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
$ 54.00K----
Operating Expense
$ 53.78M$ 76.50M$ 48.57M$ 20.69M$ 11.11M
Operating Income
$ -53.78M$ -76.50M$ -48.57M$ -20.69M$ -11.11M
Net Non Operating Interest Income Expense
$ -3.09M$ 3.03M$ -2.26M$ -568.00K-
Other Income Expense
$ -32.01M--$ -473.00K$ -184.00K
Pretax Income
$ -52.57M$ -73.47M$ -50.84M$ -21.16M$ -11.29M
Tax Provision
$ -4.62M-$ -290.00K$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -47.95M$ -73.47M$ -50.55M$ -21.16M$ -11.29M
Basic EPS
$ -1.60--$ -1.89$ -0.99
Diluted EPS
$ -2.00$ -3.59$ -5.19$ -1.89$ -0.99
Basic Average Shares
$ 106.49M$ 20.45M$ 9.73M$ 11.18M$ 11.39M
Diluted Average Shares
$ 106.49M$ 20.45M$ 9.73M$ 11.18M$ 11.39M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 53.78M$ 76.50M$ 48.57M$ 20.69M$ 11.11M
Net Income From Continuing And Discontinued Operation
$ -47.95M$ -73.47M$ -50.55M$ -21.16M$ -11.29M
Normalized Income
$ -35.72M--$ -21.16M$ -11.29M
Interest Expense
---$ 568.00K-
EBIT
$ -51.52M$ -73.95M$ -48.57M$ -20.69M$ -11.11M
EBITDA
$ -50.93M$ -73.53M$ -47.72M$ -20.62M$ -11.08M
Currency in USD

Sienna Biopharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis